
- Vol 38, Issue 7
Developing a Collaborative Approach to Post-Acute Sequelae of SARS-CoV-2 Infection
1 in 3 COVID-19 survivors experience persistent consequences. What can psychiatry do to help?
It is not new for viruses to have both mental and physical health consequences.
The effects of COVID-19 are expected to last for a long time, with evidence for persistent and/or delayed
This recognized phase of prolonged illness, referred to by a variety of names including long COVID-19, long-haul COVID-19, and postacute COVID-19, has been recently designated by the National Institutes of Health as
The Multifactorial Consequences of PASC
Although COVID-19 had initially been most notorious for causing respiratory pathology, with the most vulnerable patients progressing to
We have much to learn about PASC, due to the multiorgan system effects and the heterogeneity of symptoms in patients who
Vignette 1
“Alma,” a woman aged 45 years, presents with a history of hypertension and a 4-week intensive care unit (ICU) stay due to acute respiratory failure, prolonged intubation, and paralysis after contracting COVID-19. Alma’s ICU stay was complicated by a course of delirium. She had been discharged home from a rehabilitation center more than 6 months prior to her appointment.
She has been referred for ongoing symptoms of
The Mental Health Impacts of ICU Admissions
Prior to the COVID-19 pandemic, it had been increasingly recognized that survivors of ICU admissions commonly experience
Vignette 2
After contracting COVID-19, “John,” a man aged 70 years with a history of asthma, obstructive sleep apnea, diabetes, and major depression, was hospitalized for 4 days due to low oxygen levels, which required treatment with steroids.
John presents 3 months after hospitalization with worsening depression, insomnia, breathlessness, and related anxiety. His mood is also influenced by frustration with obstacles in restarting home health services. Due to a lack of assistance, it has been difficult for John to keep up with his many follow-up appointments or go to the pharmacy to pick up medications and other medical supplies. He reports being quite lonely and has not seen his out-of-state family for many months.
Identifying Predisposing Risk Factors for PASC
The outcomes for an individual after contracting COVID-19 will depend not only on the direct influence of the virus, but also on predisposing risk factors (ie,
Vignette 3
“Susan” is a woman, aged 40 years, with a prior episode of major depression that had been in remission and mild attention-deficit symptoms that had been well controlled. She presents more than 7 months after contracting COVID-19.
During her acute course, she struggled with fever, cough, headache, shortness of breath, fatigue, and anosmia. Susan was evaluated in the emergency department due to the severity of her symptoms, but she did not require hospitalization. She has had persistent symptoms of breathlessness, profound fatigue, difficulty with concentration and memory,
Symptoms of Lower Severity, but High Persistence
This clinical presentation—a patient who is younger, previously healthy, with milder acute COVID-19 symptoms and persistently impairing symptoms longitudinally—is often referred to as long COVID-19. Earlier in the pandemic,
Long COVID-19 challenges clinicians more than ever to listen to patients and break down the false dichotomy between mental and physical health. The experience of feeling trivialized and frustrated by an overemphasis on the psychological components of illness has been shared by
The presentation of neuropsychiatric symptoms after COVID-19 are heterogeneous, and to some extent they may reflect variable and multifactorial causes. The
Issues to Consider in Treatment and Recovery
Many patients slowly recover with supportive measures and symptomatic treatment.11 Much of the initial recovery recommendations focus on physical rehabilitation and support. There are not yet formalized standards of care in treatment of depression and other mental health concerns in PASC. Notably, some patients with PASC may struggle with symptoms of dysautonomia such as persistent tachycardia and/or vulnerability to orthostasis, which may diminish tolerability to some psychotropic medications.4
A number of patients with long COVID-19, similar to patients with ME/CFS, have
In addition to our standard treatments for depression, anxiety, and PTSD, there are some emerging areas of interest. Breathing exercises have been a recommendation of post–COVID-19 clinics and have benefited patients who have persistent feelings of breathlessness.
Concluding Thoughts
We are only just beginning to understand COVID-19 and its consequences. It will take multiyear studies to elucidate long-term sequelae and to understand how to best help patients. Also, this virus has further elucidated the
Dr LaSalvia is a geriatric psychiatrist at Beth Israel Deaconess Medical Center (BIDMC) and an instructor at Harvard Medical School. She is the consulting psychiatrist for the BIDMC Critical Illness and COVID-19 Survivorship Program. al Dr Keshavan is Stanley Cobb Professor and Academic Head of Psychiatry at Beth Israel Medical Center and Harvard Medical School.
References
1. Global statistics. HIV.gov. Updated November 25, 2020. Accessed May 24, 2021.
2. Yehia BR, Stephens-Shield AJ, Momplaisir F, et al.
3. Dong E, Du H, Gardner L.
4. Nalbandian A, Sehgal K, Gupta A, et al.
5. Huang C, Huang L, Wang Y, et al.
6. Logue JK, Franko NM, McCulloch DJ, et al.
7. Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ.
8. Collins FS. NIH launches new initiative to study ‘long COVID.’ National Institutes of Health. February 23, 2021. Accessed May 24, 2021.
9. Huang C, Wang Y, Li X, et al.
10. Gupta A, Madhavan MV, Sehgal K, et al.
11. Greenhalgh T, Knight M, A’Court C, Buxton M, Husain L.
12. Marra A, Pandharipande PP, Girard TD, et al.
13. Wang S, Allen D, Kheir YN, et al.
14. Wright A, Salazar A, Mirica M, et al.
15. Donovan NJ, Blazer D.
16. Ladds E, Rushforth A, Wieringa S, et al.
17. Rogers JP, Chesney E, Oliver D, et al.
18. McManimen S, McClellan D, Stoothoff J, et al.
19. Perez DL, Keshavan MS, Scharf JM, et al.
20. Keshavan MS, Price BH, Martin JB.
21. The Lancet.
22. Myalgic encephalomyelitis/chronic fatigue syndrome: treatment of ME/CFS. CDC. January 28, 2021. Accessed May 24, 2021.
23. O’Rourke M. Unlocking the mysteries of long COVID. The Atlantic. March 8, 2021. Accessed May 24, 2021.
24. Zhao H-M, Xie Y-X, Wang C;
25. Taneja MK.
26. Courtois I, Cools F, Calsius J.
27. Siu JY-M.
28. Collins F. Predicting ‘long COVID syndrome’ with help of a smartphone app. NIH Director’s Blog. March 23, 2021.
29. Sudre CH, Murray B, Varsavsky T, et al.
30. Rodriguez-Villa E, Rauseo-Ricupero N, Camacho E, et al.
31. Ferrarelli F, Keshavan MS.
Articles in this issue
about 5 years ago
What Is Resilience?about 5 years ago
Is Epstein-Barr Virus to Blame for Cognition in Schizophrenia?about 5 years ago
Faith Communities and the Well-Being of LGBTQ Youthabout 5 years ago
Shining a Spotlight on Bright Light for Acute Bipolar Depressionabout 5 years ago
Two Crises I Didn’t Train Forabout 5 years ago
Let’s Use the Pandemic to Change Mental Health Care for the Betterabout 5 years ago
Addressing Apathy in Dementiaabout 5 years ago
The Rise in Synthetic Cannabinoids and CathinonesRelated to this article

